IDEXX Laboratories, Inc. $IDXX Stock: International Assets Investment Management LLC Increases Holdings

Key Points

• International Assets Investment Management LLC increased its IDEXX Laboratories stake by 30,484.1% in the third quarter, acquiring 233,508 additional shares. The fund held 234,274 shares valued at approximately $122.3 million, while institutional investors collectively owned 87.84% of the company.
• IDEXX shares opened at $551.21, down 4.3%, with a market capitalization of $43.42 billion. The company recently exceeded quarterly earnings and revenue expectations, reporting $4.27 in EPS and $1.22 billion in revenue, while revenue rose 9.7% year over year.
• Analyst sentiment remains positive but cautious, with an overall “Moderate Buy” rating and an average price target of $721.67. Recent target changes included Jefferies lowering its target to $705 and UBS reducing its objective to $627; a company director also sold shares worth about $1.17 million.

International Assets Investment Management LLC grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 30,484.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 234,274 shares of the company's stock after purchasing an additional 233,508 shares during the quarter. IDEXX Laboratories comprises approximately 0.9% of International Assets Investment Management LLC's investment portfolio, making the stock its 15th biggest holding. International Assets Investment Management LLC owned about 0.30% of IDEXX Laboratories worth $122,336,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Aurora Investment Managers LLC. acquired a new position in IDEXX Laboratories during the 2nd quarter valued at about $2,442,000. National Pension Service boosted its holdings in IDEXX Laboratories by 5.6% in the second quarter. National Pension Service now owns 129,305 shares of the company's stock worth $68,071,000 after acquiring an additional 6,885 shares in the last quarter. NewEdge Advisors LLC boosted its holdings in IDEXX Laboratories by 60.9% in the first quarter. NewEdge Advisors LLC now owns 15,221 shares of the company's stock worth $8,552,000 after acquiring an additional 5,761 shares in the last quarter. Arizona State Retirement System boosted its holdings in IDEXX Laboratories by 4.9% in the second quarter. Arizona State Retirement System now owns 22,772 shares of the company's stock worth $11,988,000 after acquiring an additional 1,074 shares in the last quarter. Finally, Howard Capital Management LLC purchased a new stake in shares of IDEXX Laboratories during the third quarter worth about $1,249,000. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Stock Down 4.3%

IDXX opened at $551.21 on Friday. The stock has a market capitalization of $43.42 billion, a price-to-earnings ratio of 38.76 and a beta of 1.55. IDEXX Laboratories, Inc. has a fifty-two week low of $500.61 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The company has a fifty day moving average of $534.27 and a two-hundred day moving average of $574.09.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The firm had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same quarter last year, the firm posted $3.50 EPS. The business's revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, research analysts expect that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of recent analyst reports. Jefferies Financial Group lowered their target price on shares of IDEXX Laboratories from $795.00 to $705.00 and set a "buy" rating for the company in a research note on Tuesday, October 20th. BTIG Research dropped coverage on shares of IDEXX Laboratories in a research note on Friday. They set a "buy" rating on the stock. Citigroup raised their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday, August 5th. UBS Group lowered their price objective on shares of IDEXX Laboratories from $670.00 to $627.00 and set a "neutral" rating for the company in a research note on Tuesday. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Eight investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and an average price target of $721.67.

Insider Transactions at IDEXX Laboratories

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the company's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director owned 9,568 shares of the company's stock, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.79% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX's companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.